Reportlinker Adds Pipeline and Commercial Insight: Neuropathic Pain - Pipeline Setbacks Prolong Pfizer's Supremacy

News provided by

Apr 28, 2011, 06:49 ET

NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0487124/Pipeline-and-Commercial-Insight-Neuropathic-Pain---Pipeline-setbacks-prolong-Pfizers-supremacy.html

Introduction

At present, only six drugs are indicated for the treatment of neuropathic pain. In 2010, two significant events impacted the neuropathic pain market: the launch of Qutenza (8% capsaicin patch; NeurogesX/Astellas) in the US and EU; and the high-profile failure of ralfinamide (NW-1029; Newron) for the treatment of neuropathic low back pain.

Features and benefits

* Analysis of patient segmentation, epidemiology, current treatment approaches, and clinical unmet needs.* In depth analysis of historic (2005–09) and future (2010–19) seven major market prescription sales dynamics.* Discussion of R&D dynamics and pipeline trends in the neuropathic pain market.* Commercial and clinical assessment of key late-stage pipeline drugs with country-specific sales forecasts to 2019.* Insight provided by eight international key opinion leaders.

Highlights

The neuropathic pain market is expected to achieve peak sales of $4.1bn over the forecast period (2010–19) across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK).In addition to existing brands expanding into new regions, Datamonitor forecasts a total of eight pipeline candidates to enter the neuropathic pain market over the forecast period (2010–19) across the seven major markets. The broad label approval of Nucynta ER (extended-release tapentadol; Johnson & Johnson/Grunenthal) will drive market growth, while the launch of novel and topical agents will broaden treatment options.

Your key questions answered

* Who will be the winners and losers in the future neuropathic pain market?* What are the key unmet needs in the treatment of neuropathic pain?* What are the most promising drug candidates in development for the potential treatment of neuropathic pain?* Which neuropathic pain subtypes represent the most lucrative indications in which to seek regulatory approval?

Executive Summary

Strategic scoping and focus

Datamonitor insight into the neuropathic pain market

Related reports

OVERVIEW

Catalyst

Summary

1. PATIENT POTENTIAL

Key findings

Definition of neuropathic pain

Neuropathic pain can be defined by location, etiology, and severity

Diagnosis of neuropathic pain

Patient segmentation

Segmentation of neuropathic pain largely depends on the subtype

Segmentation of neuropathic pain differs depending on the symptoms

Epidemiology of neuropathic pain in the seven major markets

Neuropathic low back pain is the most prevalent of the neuropathic pain indications, affecting an estimated 29 million individuals across the seven major markets

Diabetic neuropathic pain affects an estimated 683,000 patients across the seven major markets

HIV-related neuropathic pain affects an estimated 332,000 people in the seven major markets

Post-herpetic neuralgia affects an estimated 307,000 people across the seven major markets

Other neuropathic pain subtypes

Current management of neuropathic pain

Treatments of neuropathic pain can involve pharmacological and non-pharmacological approaches

Consequences of inadequately treated neuropathic pain

Unmet need in neuropathic pain

The primary unmet need is improved efficacy in pain reduction and management

After efficacy, improved side-effect profile is the second most important unmet need

Reduction in pill burden will be increasingly important in the future with the use of combination therapies

Fewer drug-drug interactions will strengthen pipeline agents profile for use as a conjunctive therapy

Reduced time to onset of action is the least important unmet need

2. MARKET OVERVIEW

Market definition for this report

Seven major markets

Key events impacting the neuropathic pain market

Current and future market overview

Current and future market assessment

Japan

Current and future market assessment

Five major European markets

Current and future market assessment

France

Germany

Italy

Spain

3. BRAND DYNAMICS

Overview of competitive landscape

Six treatments are currently marketed for neuropathic pain

Off-label prescribing

US formulary tier status for leading brands

Lyrica (pregabalin; Pfizer)

Drug overview

Drug profile

Product positioning

SWOT analysis

Brand forecast to 2019

Cymbalta (duloxetine; Eli Lilly/Shionogi)

Drug overview

Drug profile

Product positioning

SWOT analysis

Brand forecast to 2019

Lidoderm (5% lidocaine patch; Endo/Grunenthal/Teikoku)

Drug overview

Drug profile

Product positioning

SWOT analysis

Brand forecast to 2019

Qutenza (8% capsaicin patch; NeurogesX/Astellas)

Brand overview

Brand profile

Product positioning

SWOT analysis

Brand forecast to 2019

Other brands indicated for neuropathic pain

Neurontin (gabapentin; Pfizer)

Tegretol XR/CR (extended-release carbamazepine; Novartis)

4. PIPELINE OVERVIEW AND R&D DYNAMICS

Pipeline overview

Clinical pipeline

Classification of pipeline products

Glutamate receptor modulators

Ion channel modulators

GABA modulators

Others

Comparative forecasts

Datamonitor pipeline assessment summary

Definition of current comparator therapy

Pfizer's Lyrica is Datamonitor's comparator therapy for non-topical neuropathic pain treatments

Endo's Lidoderm is the topical comparator therapy

Pipeline candidates need to address efficacy, dosing regime, and side effects

5. R&D APPROACH

R&D approach differs depending on the geographic market

General neuropathic pain provides a broader customer base in the EU and Japan

US approval requires evidence in each neuropathic pain subtype

Clinical trial design in neuropathic pain

Choice of endpoint is the key clinical trial design factor in neuropathic pain

Clinical trial endpoints in neuropathic pain

A key challenge inherent in neuropathic pain clinical trials is recruitment of a homogenous, treatment-naïve patient population

6. PIPELINE ANALYSIS AND FORECASTS: GLUTAMATE MODULATORS

Pipeline summary

NP-1 (amitriptyline and ketamine; EpiCept)

Drug overview

Drug profile

Development overview

Clinical trial data

SWOT analysis

Datamonitor's drug assessment score card for NP-1

Clinical attractiveness

Commercial attractiveness

Satisfaction of unmet needs

Brand forecast to 2019

AVP-923 (dextromethorphan hydrobromide and quinidine sulfate; IriSys/Avanir)

Drug overview

Drug profile

Development overview

Clinical trial data

SWOT analysis

Datamonitor drug assessment score card for AVP-923

Clinical attractiveness

Commercial attractiveness

Satisfaction of unmet needs

Forecasts to 2019

Other glutamate modulators

NT11624 (dimiracetam; Brane Discovery/Neurotune)

7. PIPELINE ANALYSIS AND FORECASTS: ION CHANNEL MODULATORS

Pipeline summary

Ralfinamide (NW-1029; Newron)

Drug overview

Drug profile

Development overview

Clinical trial data

SWOT analysis

Datamonitor drug assessment score card for ralfinamide

Clinical attractiveness

Commercial attractiveness

Satisfaction of unmet needs

Brand forecast to 2019

Eladur (bupivacaine patch; Durect/King/Pfizer)

Drug overview

Drug profile

Development overview

Clinical trial data

SWOT analysis

Datamonitor drug assessment score card for Eladur

Clinical attractiveness

Commercial attractiveness

Satisfaction of unmet needs

Brand forecast to 2019

Other ion channel modulators

BIA 2-093 (eslicarbazepine acetate; Bial)

2PX (strontium chloride; SantoSolve AS)

8. PIPELINE ANALYSIS AND FORECASTS: GABA MODULATORS

Pipeline summary

DM-1796 (extended-release gabapentin; Depomed/Abbott)

Drug overview

Drug profile

Development overview

Clinical trial data

SWOT analysis

Datamonitor drug assessment score card for DM-1796

Clinical attractiveness

Commercial attractiveness

Satisfaction of unmet needs

Brand forecast to 2019

Horizant (gabapentin enacarbil; XenoPort/GlaxoSmithKline/Astellas)

Drug overview

Drug profile

Development overview

Clinical trial data

SWOT analysis

Datamonitor drug assessment score card for Horizant

Clinical attractiveness

Commercial attractiveness

Satisfaction of unmet needs

Brand forecast to 2019

9. PIPELINE ANALYSIS AND FORECASTS: OTHER

Pipeline summary

Nucynta ER (extended-release tapentadol HCl; Johnson & Johnson/Grunenthal)

Drug overview

Drug profile

Development overview

Clinical trial data

SWOT analysis

Datamonitor drug assessment score card for Nucynta ER

Clinical attractiveness

Commercial attractiveness

Satisfaction of unmet needs

Brand forecast to 2019

ARC-4558 (clonidine HCl; Arcion)

Drug overview

Drug profile

Development overview

Clinical trial data

SWOT analysis

Datamonitor drug assessment score card for ARC-4558

Clinical attractiveness

Commercial attractiveness

Satisfaction of unmet needs

Brand forecast to 2019

Other pipeline candidates

Sativex (tetrahydrocannabinol and cannabidiol; GW Pharma/Bayer)

ADL5859/PF4856880 (Adolor)

BIBLIOGRAPHY

Patient potential

Journals